Bio-Techne to Present at the BofA Securities 2025 Health Care Conference

5/8/25 7:00:00 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $TECH alert in real time by email

MINNEAPOLIS, May 8, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that Kim Kelderman, President and Chief Executive Officer, will present at the BofA Securities 2025 Health Care Conference on Tuesday, May 13, 2025, at 10:40 a.m. PDT. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar.

About Bio-Techne

Bio-Techne Corporation (NASDAQ:TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With hundreds of thousands of products in its portfolio, Bio-Techne generated approximately $1.2 billion in net sales in fiscal 2024 and has over 3,100 employees worldwide. For more information on Bio-Techne and its brands, please visit https://www.bio-techne.com or follow the Company on social media at: Facebook, LinkedIn, Twitter or YouTube.

Contact:	David Clair, Vice President, Investor Relations & Corporate Development
	[email protected]
	612-656-4416

View original content to download multimedia:https://www.prnewswire.com/news-releases/bio-techne-to-present-at-the-bofa-securities-2025-health-care-conference-302448431.html

SOURCE Bio-Techne Corporation

Get the next $TECH alert in real time by email

Recent Analyst Ratings for

$TECH

Date	Price Target	Rating	Analyst
5/30/2025	$59.00	Overweight	Wells Fargo
4/9/2025		Overweight → Sector Weight	KeyBanc Capital Markets
3/18/2025	$75.00	Outperform	Evercore ISI
2/19/2025	$88.00 → $68.00	Outperform → Neutral	Robert W. Baird
5/22/2024	$85.00	Buy → Neutral	Citigroup
2/8/2024	$80.00	Sector Outperform	Scotiabank
2/2/2024	$65.00	Buy → Hold	Stifel
12/7/2023	$80.00	Buy	UBS

More analyst ratings

Bio-Techne to Present at the BofA Securities 2025 Health Care Conference

Chat with this insight

Recent Analyst Ratings for
$TECH

$TECH
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Herr Amy E. exercised 1,280 shares at a strike of $44.33 and sold $63,705 worth of shares (1,280 units at $49.77) (SEC Form 4)

Director Higgins John L exercised 12,000 shares at a strike of $21.84, increasing direct ownership by 25% to 60,196 units (SEC Form 4)

SVP - General Counsel Bohnen Shane converted options into 2,260 shares and covered exercise/tax liability with 747 shares, increasing direct ownership by 90% to 3,194 units (SEC Form 4)

Bio-Techne to Present at the BofA Securities 2025 Health Care Conference

Chat with this insight

Recent Analyst Ratings for $TECH

$TECH Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Herr Amy E. exercised 1,280 shares at a strike of $44.33 and sold $63,705 worth of shares (1,280 units at $49.77) (SEC Form 4)

Director Higgins John L exercised 12,000 shares at a strike of $21.84, increasing direct ownership by 25% to 60,196 units (SEC Form 4)

SVP - General Counsel Bohnen Shane converted options into 2,260 shares and covered exercise/tax liability with 747 shares, increasing direct ownership by 90% to 3,194 units (SEC Form 4)

Recent Analyst Ratings for
$TECH

$TECH
Insider Trading